Chardan Capital reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report released on Tuesday, Benzinga reports. Chardan Capital currently has a $25.00 price target on the stock. Separately, HC Wainwright reaffirmed a buy rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a […]